
PCRX
Pacira Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
22.740
Open
22.530
VWAP
22.30
Vol
767.97K
Mkt Cap
1.04B
Low
21.940
Amount
17.13M
EV/EBITDA(TTM)
6.58
Total Shares
46.30M
EV
1.13B
EV/OCF(TTM)
6.45
P/S(TTM)
1.52
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
203.52M
+8.68%
0.874
-3.98%
182.92M
+8.51%
0.669
-15.32%
183.12M
+2.87%
0.710
-20.19%
Estimates Revision
The market is revising Downward the revenue expectations for Pacira BioSciences, Inc. (PCRX) for FY2025, with the revenue forecasts being adjusted by -1.85% over the past three months. During the same period, the stock price has changed by -16.91%.
Revenue Estimates for FY2025
Revise Downward

-1.85%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-2.92%
In Past 3 Month
Stock Price
Go Down

-16.91%
In Past 3 Month
7 Analyst Rating

82.93% Upside
Wall Street analysts forecast PCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCRX is 41.25 USD with a low forecast of 26.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
1 Sell
Moderate Buy

82.93% Upside
Current: 22.550

Low
26.00
Averages
41.25
High
65.00

82.93% Upside
Current: 22.550

Low
26.00
Averages
41.25
High
65.00
Truist
Hold
to
Buy
upgrade
$28 -> $30
2025-07-25
New
Reason
Truist
Price Target
$28 -> $30
2025-07-25
New
upgrade
Hold
to
Buy
Reason
Truist upgraded Pacira (PCRX) to Buy from Hold with a price target of $30, up from $28. The firm, which thinks Pacira's fundamental profile has "materially improved," cites generic resolution on its lead asset, NOPAIN uptake plus the latest partnership with Johnson & Johnson (JNJ). The firm sees a "solid" buying opportunity, the analyst added.
HC Wainwright & Co.
Oren Livnat
Strong Buy
Maintains
$48 → $65
2025-04-08
Reason
HC Wainwright & Co.
Oren Livnat
Price Target
$48 → $65
2025-04-08
Maintains
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$32
2025-04-08
Reason
Needham
Serge Belanger
Price Target
$32
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Oren Livnat
Strong Buy
Maintains
$57 → $70
2025-02-28
Reason
HC Wainwright & Co.
Oren Livnat
Price Target
$57 → $70
2025-02-28
Maintains
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Maintains
$30 → $32
2025-02-28
Reason
Needham
Serge Belanger
Price Target
$30 → $32
2025-02-28
Maintains
Strong Buy
Reason
Barclays
Balaji Prasad
Buy
Maintains
$17 → $24
2025-02-28
Reason
Barclays
Balaji Prasad
Price Target
$17 → $24
2025-02-28
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Pacira Biosciences Inc (PCRX.O) is 7.43, compared to its 5-year average forward P/E of 13.93. For a more detailed relative valuation and DCF analysis to assess Pacira Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
13.93
Current PE
7.43
Overvalued PE
19.62
Undervalued PE
8.25
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
9.74
Current EV/EBITDA
5.71
Overvalued EV/EBITDA
13.03
Undervalued EV/EBITDA
6.45
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
3.09
Current PS
1.36
Overvalued PS
4.50
Undervalued PS
1.68
Financials
Annual
Quarterly
FY2025Q1
YoY :
+1.08%
168.92M
Total Revenue
FY2025Q1
YoY :
-45.90%
8.18M
Operating Profit
FY2025Q1
YoY :
-46.41%
4.81M
Net Income after Tax
FY2025Q1
YoY :
-47.37%
0.10
EPS - Diluted
FY2025Q1
YoY :
-41.83%
26.91M
Free Cash Flow
FY2025Q1
YoY :
+12.92%
71.21
Gross Profit Margin - %
FY2025Q1
YoY :
-10.71%
22.68
FCF Margin - %
FY2025Q1
YoY :
-46.93%
2.85
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 3136.27% over the last month.
Sold
0-3
Months
523.4K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
16.2K
USD
1
0-12
Months
6.4K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
6
215.7K
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 695.83% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
17.2K
Volume
Months
6-9
1
2.2K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 3136.27% over the last month.
Sold
0-3
Months
523.4K
USD
2
3-6
Months
0.0
USD
0
6-9
Months
16.2K
USD
1
0-12
Months
6.4K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
6
215.7K
USD
Months
PCRX News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
08:04:17
Pacira collabs with J&J's MedTech to expand market reach of ZILRETTA

2025-06-11 (ET)
2025-06-11
08:03:43
Pacira announces new long-term follow-up data from Phase 1 trial on PCRX-201

2025-06-05 (ET)
2025-06-05
08:02:13
Pacira reports inducement grants under Nasdaq listing rule

Sign Up For More Events
Sign Up For More Events
News
7.5
07-23NASDAQ.COMPacira, J&J MedTech Partner To Expand Reach Of ZILRETTA For Osteoarthritis Knee Pain
7.5
07-22SeekingAlphaPacira signs partnership with JNJ to expand Zilretta
7.0
07-16PRnewswireInvestors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit
Sign Up For More News
People Also Watch

SKE
Skeena Resources Ltd
15.460
USD
-3.86%

SERV
Serve Robotics Inc
11.650
USD
+2.19%

UUUU
Energy Fuels Inc
10.010
USD
+0.50%

OPEN
Opendoor Technologies Inc
2.540
USD
+4.96%

BBDC
Barings BDC Inc
9.580
USD
+0.10%

DCO
Ducommun Inc
90.450
USD
+1.98%

MFA
MFA Financial Inc
9.480
USD
+0.64%

GYRE
Gyre Therapeutics Inc
7.640
USD
+3.52%

TPB
Turning Point Brands Inc
78.290
USD
+0.38%

PARR
Par Pacific Holdings Inc
31.430
USD
+0.10%
FAQ

What is Pacira Biosciences Inc (PCRX) stock price today?
The current price of PCRX is 22.55 USD — it has increased 3.35 % in the last trading day.

What is Pacira Biosciences Inc (PCRX)'s business?

What is the price predicton of PCRX Stock?

What is Pacira Biosciences Inc (PCRX)'s revenue for the last quarter?

What is Pacira Biosciences Inc (PCRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pacira Biosciences Inc (PCRX)'s fundamentals?

How many employees does Pacira Biosciences Inc (PCRX). have?
